Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.
Measuring CAR-T cell levels after infusion may help predict treatment response and guide personalized monitoring intensity.
This PubMed record reports that thus, incorporating quantitative CAR-T enumeration into clinical practice may dynamically refine risk stratification post-infusion and guide individualised management, such as the frequency of monitoring for progressive disease in the era of effective subsequent therapies. It provides prospective cohort study evidence relevant to Hematologic malignancies.
What the study was
- Study design
- Prospective cohort study
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- British journal of haematology
Why it surfaced
Conservative rapid triage based on the PubMed abstract and citation metadata; prospective cohort study with treatment innovation relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.